The most common adverse effects are reactions at the injection site, which occurred in 43 to 45% of people in studies (as compared to 38% under placebo). Hypersensitivity reactions occurred in fewer than 1% of patients.
Fremanezumab
Ustekinumab
Tralokinumab
Olaratumab
Evolocumab
Bezlotoxumab
Alirocumab
Durvalumab